![]() Updated Methodology, Post-Rebate Adjustment, Current Expenditure (2020) Previous Methodology, Pre-Rebate Adjustment, Current Expenditure (2020) The improved methodology reduced the estimate of health care expenditure in 2020 to nearly $2.80 trillion, from more than $2.95 trillion in the Health Care Satellite Account data released in February.Ĭomparison of Previous and Updated Methodology, Disease-Level Diseases BEA's new methodology uses drug price data from a private data aggregator, SSR Health LLC's US Brand Rx Net Pricing Tool, to estimate manufacturer rebatesīEA mapped the SSR Health data to pharmaceutical claims and subtracted drug-specific rebates from prescription spending. Rebate negotiations are confidential, which has prevented researchers from estimating the magnitude of the discounts. Manufacturer rebates are discounts provided by drugmakers to intermediary companies, called pharmacy benefit managers, after drugs are dispensed. This more-detailed, disease-centered view supplements BEA's traditional economic statistics for a deeper understanding of health care spending patterns and policies. The Health Care Satellite Account measures spending on treatment of medical conditions, such as cancer or diabetes. After subtracting the rebates, BEA's estimate of health care spending in 2020 was reduced by $158 billion, or 5.3 percent, from the previous estimate for 2020. The Bureau of Economic Analysis today updated its supplemental health care statistics with an improved methodology that shows the growing role of prescription drug rebates over two decades.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |